Tyrosine kinase inhibitors (TKIs) targeting ABL1 catalytic activity have markedly improved Chronic Myeloid Leukemia (CML) outcomes, inducing unprecedented and durable therapeutic responses. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.